News Archives


Sanofi Pasteur introduces a new option for flu vaccination. Intanza influenza vaccine has a tiny microneedle more than 10 times smaller than regular flu shot needles, yet it is just as immunogenic as traditional intramuscular flu shots.

With its 1.5 mm microneedle, Intanza provides a minimally invasive vaccination, and more than 80 per cent of patients reported no pain or hardly any pain upon injection.

Intanza offers an alternative to intramuscular injections that is equally effective and while increasing patient comfort.

Please click here to read the full news release.


Avenue is sanofi pasteur’s newsletter for its Connaught Campus neighbours. It's designed to keep them apprised of important events and ongoing projects at our site. This issue addresses some of the questions posed at our community forum on June 24. Nearly 200 local residents attended this information session to hear about our company’s re-zoning application. More than 40 neighbours also took an outdoor guided tour in July to learn more about sanofi pasteur’s environmental initiatives and exciting innovations.

Please click here to access a copy of Avenue.


Sanofi Pasteur President Mark Lievonen was interviewed on the CBC’s Lang & O’Leary Exchange at 7 p.m. on Friday, June 4.

During the interview Mark discussed sanofi pasteur’s history and the importance of innovation to being a world leader in vaccine research and development, manufacturing and commercialization.

Please click here to access Mark's interview. The June 4th episode should come up automatically. If it doesn’t, select the June 4th episode from the six featured episodes of the Lang & O’Leary Exchange listed at the bottom of the screen. 

Mark’s interview starts at the 15 minute mark.


Envisioning better strategies for dealing with cardiac disease

Montreal May 26, 2010 – Our ability to mend damaged and diseased hearts came a long way in the 20th century, as procedures such as coronary bypass procedures became common, life-saving operations. If the work being conducted at Toronto’s McEwan Centre for Regenerative Medicine is any indication, we can expect even more dramatic progress to dominate the 21st century.

Macleans magazine writer Kate Lunau has foreshadowed that progress in an article that has earned her this year’s sanofi pasteur Medal For Excellence In Health Research Journalism. “Growing a new heart,” which appeared in the publication’s 25 February 2009 issue, provides an introduction to promising techniques for regenerating and replacing heart cells as a way of treating ailments in this organ. The field represents a complex branch of biotechnology that readers might otherwise find daunting, but Ms. Lunau’s treatment of the subject makes for compelling reading.

Click here to read the entire press release.


On Sunday, February 7, Garry Galley, former NHL defenseman and current colour commentator for Hockey Night in Canada was joined by infectious disease expert Dr. Gary Garber to raise awareness among junior hockey players and hockey enthusiasts about the importance of broad protection against the devastation of meningococcal meningitis. At the Ottawa 67s’ game at the Urbandale Centre arena in Ottawa, the pair educated spectators including families and youth about meningitis prevention and protection.

Four of the five bacterial strains that cause meningococcal meningitis are vaccine-preventable (A, C, Y and W-135). Menactra® is the only conjugate vaccine that provides protection against all four vaccine-preventable meningococcal strains. Over the last five years, Menactra® has been used to immunize over 29 million people worldwide.